EP2231126A2 - Oral dispersable tablet - Google Patents

Oral dispersable tablet

Info

Publication number
EP2231126A2
EP2231126A2 EP08856436A EP08856436A EP2231126A2 EP 2231126 A2 EP2231126 A2 EP 2231126A2 EP 08856436 A EP08856436 A EP 08856436A EP 08856436 A EP08856436 A EP 08856436A EP 2231126 A2 EP2231126 A2 EP 2231126A2
Authority
EP
European Patent Office
Prior art keywords
tablet
tablet according
active agent
group
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08856436A
Other languages
German (de)
French (fr)
Inventor
Tobias Laich
Thomas Steenpass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to EP08856436A priority Critical patent/EP2231126A2/en
Publication of EP2231126A2 publication Critical patent/EP2231126A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention is directed to an oral disintegratable tablet which exhibits oral disintegratability of not more than 60 seconds.
  • the tablet for oral administration comprises an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.
  • Oral dispersable tablets are in principle not different from common immediate release (IR) tablets. They should be mechanically stable, to allow handling during technical operations and handling by the patient or customer. Their disintegration time in aqueous environment should be fast and complete. A softening under the conditions of release, so that weak mechanical stress is sufficient for complete dispersion, is also acceptable.
  • IR immediate release
  • tablets containing gas-developing mixtures of at least one acid component (like e.g. citric acid) and at least one basic component in form of a carbonate or hydrogen-carbonate are described e.g. in US 2002/01 10578.
  • Another common method is the use of rapidly soluble tablet excipients like e.g. sugar alcohols (Mannitol, Sorbitol, Xylitol, Erythritol etc.), sugars or specialized forms of these like PharmaburstTM or F-MeltTM. Rapid disintegration is a result of the dissolution of these excipients.
  • Another difficulty in the rapid disintegration in the oral cavity is the limited amount of liquid that is present.
  • the liquid inside the oral cavity is of higher viscosity.
  • the amount of liquid and its viscosity is not constant.
  • the amount of liquid consumed smoking-status
  • Highly porous tablet structures, into which liquid can easily penetrate are therefore also common in the field of oral dispersable tablets.
  • Several specialized manufacturing technologies ensure highly porous tablet structures.
  • the geometry of the tablet can also influence the disintegration time. Short ways for liquid penetration are preferred. This prerequisite also influences the tablet shape and geometry.
  • the desired optimal geometry also has to consider mechanical stability, as described already.
  • the costs are important.
  • the manufacturing cost should be as low as possible. This can best be achieved by using established standard technologies and keeping the manufacturing process as lean as possible. Any additional manufacturing step would increase cost and has to be avoided. Also the use of specialized excipients tends to increase the costs, as these are more expensive than standard excipients.
  • the target group for the application of oral dispersable tablets can be found in patients with difficulties in swallowing tablets or in groups were water for the intake of normal tablets is not readily available. In some markets the convenience of taking tablets without water has a high preference. In all cases, the disintegration time of the tablet should be short and the patient/costumer should get the impression of something happening with the tablet inside his mouth. This perception of disintegrating action helps the patients/costumers expectation of a positive influence of the active principle(s) on his/her state or health.
  • JP 9071523 describes the formulation of oral dispersable tablet.
  • MCC microcrystalline cellulose
  • L-HPC low substituted hydroxyl-propyl Cellulose
  • WO 2004091585 describes the use of Prosolv (silicified microcrystalline Cellulose) for the formulation of oral dispersable tablets.
  • Prosolv is a trademark excipient and further described in the US 6471994 as a new tablet excipient also for the use with oral dispersable tablets.
  • surfactants and hydrophilic, wetting polymers like Poloxamer, are used to aid the wettability of active ingredients (drug substance(s)) or increase their bioavailibilty by enhancing their dissolution.
  • surfactants can be used to reduce the viscosity of the aqueous media inside the oral cavity, independent of the wettability of the active. This effect can be promoted by the use of one or more sweet tasting substances inside the formulation. Salt (NaCl), acid components or intensive flavour can have a similar effect and would also reduce the viscosity of the aqueous media inside the oral cavity.
  • the present invention is directed to a non-effervescent tablet for oral administration, comprising an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable
  • the said tablet exhibits oral disintegratabihty in not more than 60 seconds
  • the tablet exhibits oral disintegratabihty in not more than 30 seconds
  • the tablet exhibits oral disintegratabihty in not less than 5 seconds
  • Most preferred the tablet exhibits oral disintegratabihty in not less than 2 seconds
  • the water insoluble carrier in the tablet is selected from the group Cellulose, microcrystalline Cellulose or sihcified microcrystalline Cellulose or mixtures thereof
  • the sihcified microcrystalline cellulose is contained in an amount within the range of 20% to 90% preferably within the range of 25% to 60%
  • the said sihcified microcrystalline cellulose contains 1 -5% silicon dioxide
  • the tablet sihcified microcrystalline cellulose in the tablet has an average particle size within the range of 20-300 ⁇ m
  • the desintegrant in the tablet is selected from the group consisting of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, crosscarmelose sodium, crosspovidone (crosslinked Polyvinylpyrohdone), sodium starch glycolate, starch, and combinations thereof
  • Preferrabihty the disintegrant is low substituted hydroxypropyl cellulose or crosspovidone (crosslinked Polyvinylpyrohdone) or combinations thereof
  • the disintegrant is contained in the tablet in an amount of 0 5% to 50%
  • the surfactant in the tablet is selected from the group Sodium dodecylsulfate, Polyoxyethylen Sorbitan fatty acid esters (Tweens), Polyoxyethylene Stearates, Sorbitan fatty acid esters (Spans)
  • the tablet according to the invention has a friability of less than 1 %
  • the tablet according to the invention does not contain a water soluble binder
  • the tablet according to to the invention may further comprises at least one additional excipient selected from the group consisting of taste masking agents, sweeteners, lubricants, stabilizers, preservatives, and pH-adjustors
  • the active agent in the tablet according to the invention is selected from the group consisting of pharmaceutical active agents, nutrients, nut ⁇ ceuticals, and cosmetics
  • the active agent can be one or more vitamins
  • the active agent can also be one or more pharmaceutically active agent(s)
  • the said pharmaceutically active agent can be present in the form of coated particles containing said pharmaceutically active agent
  • the coating can be an extended release or an enteric coating
  • the tablet according to the invention is a tablet, wherein said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulce ⁇ cs, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistamines
  • said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulce ⁇ cs, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistamines
  • the said pharmaceutically active agent can be selected from the group consisting of lbuprofen, acetominophen, piroxicam, leflunomide, ondansetron, granisetron, paracetamol, carbamazepin, lamot ⁇ gine, clozapine, olanzapine, risperidone, citalopram, paroxetine, sertraline, fluoxetine, fluvoxamine, zopiclon, Zolpidem, cimetidine, ranitidine, omeprazole, metoclopramide, cisapride, dompe ⁇ don, zafirlukast, montelukast, prarnipexol, selegiline, Zolpidem, zopiclon, doxazosin, terazosin, atenolol, bisoprolol, amlodipme, nifedipine, diltiazem, enalap ⁇ l, cap
  • the pharmaceutical orally disintegratable non-effervescent tablet is one which consists essentially of 20% to 90% sihcified microcrystalline cellulose or cellulose or microcrystalline cellulose, 0% to 20% of low substituted hydroxypropyl cellulose, 0% to 20% crosslinked Polyvinylpyrohdone, a lubricant, a surfactant and an effective amount of a pharmaceutically active agent, wherein said tablet exhibits disintegration within 1 to 15 seconds when tested in an in vitro disintegration test
  • the tablet can further comprise flavorants, colorants, or both
  • the invention is further directed to the use of a surfactant for making an orally disintegratable non- effervescent pharmaceutical tablet
  • a surfactant for making an orally disintegratable non- effervescent pharmaceutical tablet
  • the present invention provides also a process of rapidly releasing an active agent from a solid tablet, which comprises disintegrating a tablet as described above, by placing the tablet in a water environment
  • the said water environment is an oral cavity or is a waterfilled container
  • Insoluble excipients can be either of inorganic origin (like salts e g Calcium Phosphate, Calcium sulfate,
  • Suitable disintegrants in this respect are e g swellable polymers, crosslinked swellable polymers, hydrophilic polymers or other substances which take up water and with that increasing their volume
  • Pharmaceutically common are Crosscarmellose, crosslinked Polyvinylpyrohdone, L-HPC or Sodium starch glycolate
  • Other soluble excipients such as sugars (Lactose, Saccarose, Glusose, Fructose, Maltose) sugar alcohols (Mannitol, Sorbitol, Xyhtol, Eryth ⁇ tol) or soluble actives can be used, as long as their proportion is not to high and their mean particle size remains above 50 ⁇ m
  • sugars Limitose, Saccarose, Glusose, Fructose, Maltose
  • sugar alcohols Mannitol, Sorbitol, Xyhtol, Eryth ⁇ tol
  • soluble actives can be used, as long as their
  • soluble actives For the incorporation of soluble actives it was found, that their particle size has an influence on tablet disintegration It is advantageous to have the particles not to small in this case A particle size of greater than 50 ⁇ m (mean value of the distribution) was found to yield the desired tablet properties If solubility of the active(s) is high, or time for dissolution is short, greater mean particle sizes are preferred The way in which the particle size is increased is not important Larger crystals work as good as agglomerates made by granulation (wet- or dry-granulation methods can be used)
  • Desired tablet properties are sufficient mechanical stability (expressed as tensile strength and friability), rapid disintegration (expressed as disintegration time using the method described in the European Pharmacopia (European Pharmacopia 5 lh edition 2007 (5 8) Method 2 9 1 , using water at 37°C and the disk), acceptable mouth feeling and taste With the described formulation principle pharmaceutically active substances (drug substances) of different solubility can be formulated.
  • Drug substances can either be soluble (like e g the oral Antidiabetics Acarbose or Miglitol) up to insoluble (like e g Nifedipine)
  • soluble drug substances a special definition (fraction) of the particle size can be advantageous with respect to disintegration time, content uniformity and tablet hardness
  • the particles of the pharmaceutically active substances could be crystals or agglomerates
  • the particle size of the pharmaceutically active substances can be 50 ⁇ m-1000 ⁇ m, preferably 100 ⁇ m-800 ⁇ m, more preferably 125 ⁇ m-630 ⁇ m, and most preferably 125 ⁇ m-800 ⁇ m
  • the pharmaceutically active substances acarbose, miglitol and voghbose
  • the tablets can be obtained by mixing the given components (except for the lubricant Na-stearyl- fumerat) in a suitable mixing device (e g Turbula mixer or tumble blender) for 10 minutes Then add the lubricant and mix for another 5 minutes
  • a suitable mixing device e g Turbula mixer or tumble blender
  • the Acarbose is premixed with 0,5% (w/w) Na-stearyl-fumerat and compacted
  • the compacts are broken and sieved (Dry-granulation or roller-compaction) After sieving the fraction 125 ⁇ m-800 ⁇ m is used
  • the tablets disintegrate within 5-10 seconds using the described European Pharmacopia Method

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to an oral disintegratable tablet which exhibits oral disintegratability of not more than 60 seconds. The tablet for oral administration, comprises an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.

Description

Oral dispersable tablet
The present invention is directed to an oral disintegratable tablet which exhibits oral disintegratability of not more than 60 seconds. The tablet for oral administration, comprises an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.
Oral dispersable tablets are in principle not different from common immediate release (IR) tablets. They should be mechanically stable, to allow handling during technical operations and handling by the patient or customer. Their disintegration time in aqueous environment should be fast and complete. A softening under the conditions of release, so that weak mechanical stress is sufficient for complete dispersion, is also acceptable.
To improve disintegration properties, several principles are common. For example tablets containing gas-developing mixtures of at least one acid component (like e.g. citric acid) and at least one basic component in form of a carbonate or hydrogen-carbonate. Such a tablet for oral dispersibility is described e.g. in US 2002/01 10578. Another common method is the use of rapidly soluble tablet excipients like e.g. sugar alcohols (Mannitol, Sorbitol, Xylitol, Erythritol etc.), sugars or specialized forms of these like Pharmaburst™ or F-Melt™. Rapid disintegration is a result of the dissolution of these excipients.
For tablets, used for disintegration in the oral cavity, some additional properties are desirable. The resulting solution or dispersion after tablet disintegration should be easy to swallow, acceptable in its taste and mouth-feel. Hence often additional measurements for the taste-masking of the active component or components (like micro-encapsulation, coating, salt-formation, ester-formation etc.) are necessary. Furthermore aroma and/or sweeteners are used to improve the taste and the patient acceptance. Sometimes the used excipients also have a pleasant taste (sugars, sugar-alcohols) and by this property improve patient acceptance.
Another difficulty in the rapid disintegration in the oral cavity is the limited amount of liquid that is present. In comparison to water, the liquid inside the oral cavity is of higher viscosity. The amount of liquid and its viscosity is not constant. There is a variation between different subjects and even within one subject depending on the time of the day, the amount of liquid consumed (drinking-status), the consumed food etc. Highly porous tablet structures, into which liquid can easily penetrate are therefore also common in the field of oral dispersable tablets. Several specialized manufacturing technologies ensure highly porous tablet structures. The geometry of the tablet can also influence the disintegration time. Short ways for liquid penetration are preferred. This prerequisite also influences the tablet shape and geometry. The desired optimal geometry also has to consider mechanical stability, as described already.
In the manufacturing of all tablets, and also for oral dispersable tablets, the costs are important. The manufacturing cost should be as low as possible. This can best be achieved by using established standard technologies and keeping the manufacturing process as lean as possible. Any additional manufacturing step would increase cost and has to be avoided. Also the use of specialized excipients tends to increase the costs, as these are more expensive than standard excipients.
The target group for the application of oral dispersable tablets can be found in patients with difficulties in swallowing tablets or in groups were water for the intake of normal tablets is not readily available. In some markets the convenience of taking tablets without water has a high preference. In all cases, the disintegration time of the tablet should be short and the patient/costumer should get the impression of something happening with the tablet inside his mouth. This perception of disintegrating action helps the patients/costumers expectation of a positive influence of the active principle(s) on his/her state or health.
JP 9071523 describes the formulation of oral dispersable tablet. The use of microcrystalline cellulose (MCC) in combination with low substituted hydroxyl-propyl Cellulose (L-HPC) is described. A certain ratio of the two excipients is found to yield the desired tablet properties.
WO 2004091585 describes the use of Prosolv (silicified microcrystalline Cellulose) for the formulation of oral dispersable tablets. Prosolv is a trademark excipient and further described in the US 6471994 as a new tablet excipient also for the use with oral dispersable tablets.
In the development of a new formulation approach to oral dispersable tablets, the use of surfactants was studied. Surfactants and hydrophilic, wetting polymers, like Poloxamer, are used to aid the wettability of active ingredients (drug substance(s)) or increase their bioavailibilty by enhancing their dissolution. In the field of oral dispersable tablets surfactants can be used to reduce the viscosity of the aqueous media inside the oral cavity, independent of the wettability of the active. This effect can be promoted by the use of one or more sweet tasting substances inside the formulation. Salt (NaCl), acid components or intensive flavour can have a similar effect and would also reduce the viscosity of the aqueous media inside the oral cavity. Combinations of these can be used to increase the effect. Rapid tablet disintegration was found to by promoted by less hydrophobic lubricant at minimized amount, as the most commonly used Magnesium-stearate tends to slow down tablet disintegration A potent tablet disintegrant is also advantages in combination with other insoluble substances within the formulation
The present invention is directed to a non-effervescent tablet for oral administration, comprising an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable The said tablet exhibits oral disintegratabihty in not more than 60 seconds Preferably the tablet exhibits oral disintegratabihty in not more than 30 seconds More preferably the tablet exhibits oral disintegratabihty in not less than 5 seconds Most preferred the tablet exhibits oral disintegratabihty in not less than 2 seconds
The water insoluble carrier in the tablet is selected from the group Cellulose, microcrystalline Cellulose or sihcified microcrystalline Cellulose or mixtures thereof The sihcified microcrystalline cellulose is contained in an amount within the range of 20% to 90% preferably within the range of 25% to 60%
The said sihcified microcrystalline cellulose contains 1 -5% silicon dioxide The tablet sihcified microcrystalline cellulose in the tablet has an average particle size within the range of 20-300 μm
The desintegrant in the tablet is selected from the group consisting of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, crosscarmelose sodium, crosspovidone (crosslinked Polyvinylpyrohdone), sodium starch glycolate, starch, and combinations thereof Preferrabihty the disintegrant is low substituted hydroxypropyl cellulose or crosspovidone (crosslinked Polyvinylpyrohdone) or combinations thereof The disintegrant is contained in the tablet in an amount of 0 5% to 50%
The surfactant in the tablet is selected from the group Sodium dodecylsulfate, Polyoxyethylen Sorbitan fatty acid esters (Tweens), Polyoxyethylene Stearates, Sorbitan fatty acid esters (Spans)
The tablet according to the invention is one which has a tensile strength of 300 to 2000 kN/m2 (calculated as Tensile strength =2*Breakingload / (diameter * thickness *π, observed tensile failure of the measured tablet)
The tablet according to the invention has a friability of less than 1 % The tablet according to the invention does not contain a water soluble binder The tablet according to to the invention may further comprises at least one additional excipient selected from the group consisting of taste masking agents, sweeteners, lubricants, stabilizers, preservatives, and pH-adjustors The active agent in the tablet according to the invention is selected from the group consisting of pharmaceutical active agents, nutrients, nutπceuticals, and cosmetics The active agent can be one or more vitamins The active agent can also be one or more pharmaceutically active agent(s)
The said pharmaceutically active agent can be present in the form of coated particles containing said pharmaceutically active agent The coating can be an extended release or an enteric coating
The tablet according to the invention is a tablet, wherein said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulceπcs, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistamines
The said pharmaceutically active agent can be selected from the group consisting of lbuprofen, acetominophen, piroxicam, leflunomide, ondansetron, granisetron, paracetamol, carbamazepin, lamotπgine, clozapine, olanzapine, risperidone, citalopram, paroxetine, sertraline, fluoxetine, fluvoxamine, zopiclon, Zolpidem, cimetidine, ranitidine, omeprazole, metoclopramide, cisapride, dompeπdon, zafirlukast, montelukast, prarnipexol, selegiline, Zolpidem, zopiclon, doxazosin, terazosin, atenolol, bisoprolol, amlodipme, nifedipine, diltiazem, enalapπl, captopπl, ramipπl, losartan, glyceroltπnitrate, alfuzosin, finasteride, pravastatin, atorvastatin, simvastatin, gemfibrozil, metformin, terfenadine, loratadine, celecoxib, πfecoxib, and πvastigmine, as well as a pharmaceutically acceptable salt, ester, hydrate or solvate of the active agent
According to the invention the pharmaceutical orally disintegratable non-effervescent tablet is one which consists essentially of 20% to 90% sihcified microcrystalline cellulose or cellulose or microcrystalline cellulose, 0% to 20% of low substituted hydroxypropyl cellulose, 0% to 20% crosslinked Polyvinylpyrohdone, a lubricant, a surfactant and an effective amount of a pharmaceutically active agent, wherein said tablet exhibits disintegration within 1 to 15 seconds when tested in an in vitro disintegration test
The tablet can further comprise flavorants, colorants, or both
The invention is further directed to the use of a surfactant for making an orally disintegratable non- effervescent pharmaceutical tablet The present invention provides also a process of rapidly releasing an active agent from a solid tablet, which comprises disintegrating a tablet as described above, by placing the tablet in a water environment The said water environment is an oral cavity or is a waterfilled container
The percentage of insoluble parts of the tablet mixture should be above 30% by weight Insoluble excipients can be either of inorganic origin (like salts e g Calcium Phosphate, Calcium sulfate,
Magnesium carbonate, Calcium Carbonate, Sihcate(s), Oxides like Titanium dioxide, Aluminium oxide, Magnesium oxid or their respective hydrates and/or polymorphic forms) or of organic nature (like natural polymers e g Cellulose, Cellulose esters or ethers, Chitin, Chitosan, Starch,
Starch esters or ethers, Alginates, synthetic polymers e g Polyethylen, Polypropylen, Polyvinylchloπde, Polymethacrylate) If the active pπnciple(s) are insoluble or their solubility is low, they would also act as insoluble parts
Suitable disintegrants in this respect are e g swellable polymers, crosslinked swellable polymers, hydrophilic polymers or other substances which take up water and with that increasing their volume Pharmaceutically common are Crosscarmellose, crosslinked Polyvinylpyrohdone, L-HPC or Sodium starch glycolate Other soluble excipients, such as sugars (Lactose, Saccarose, Glusose, Fructose, Maltose) sugar alcohols (Mannitol, Sorbitol, Xyhtol, Erythπtol) or soluble actives can be used, as long as their proportion is not to high and their mean particle size remains above 50μm The use of this soluble excipients is also common in the field of oral dispersable tablets
For the incorporation of soluble actives it was found, that their particle size has an influence on tablet disintegration It is advantageous to have the particles not to small in this case A particle size of greater than 50μm (mean value of the distribution) was found to yield the desired tablet properties If solubility of the active(s) is high, or time for dissolution is short, greater mean particle sizes are preferred The way in which the particle size is increased is not important Larger crystals work as good as agglomerates made by granulation (wet- or dry-granulation methods can be used)
For the manufacturing of the described formulation, a direct compression manufacturing workflow can be used Thus manufacturing costs are low and standard technology can be used, which keeps investments low
Desired tablet properties are sufficient mechanical stability (expressed as tensile strength and friability), rapid disintegration (expressed as disintegration time using the method described in the European Pharmacopia (European Pharmacopia 5lh edition 2007 (5 8) Method 2 9 1 , using water at 37°C and the disk), acceptable mouth feeling and taste With the described formulation principle pharmaceutically active substances (drug substances) of different solubility can be formulated. Drug substances can either be soluble (like e g the oral Antidiabetics Acarbose or Miglitol) up to insoluble (like e g Nifedipine) In the case of soluble drug substances a special definition (fraction) of the particle size can be advantageous with respect to disintegration time, content uniformity and tablet hardness The particles of the pharmaceutically active substances could be crystals or agglomerates The particle size of the pharmaceutically active substances can be 50μm-1000μm, preferably 100μm-800μm, more preferably 125μm-630μm, and most preferably 125μm-800μm In particular useful in this particle size are the pharmaceutically active substances acarbose, miglitol and voghbose
Examples
The tablets can be obtained by mixing the given components (except for the lubricant Na-stearyl- fumerat) in a suitable mixing device (e g Turbula mixer or tumble blender) for 10 minutes Then add the lubricant and mix for another 5 minutes
This mixture is then compressed into tablets using a 9mm flat-faced beveled edged set of punches to give tablets of the given mass For double dose tablets use 13mm flat-faced beveled edged punches and compress to the double of the given mass Tablets should match the given tensile strength range (Breakingloads between 20 to 60 N)
In case of Acarbose as active, the Acarbose is premixed with 0,5% (w/w) Na-stearyl-fumerat and compacted The compacts are broken and sieved (Dry-granulation or roller-compaction) After sieving the fraction 125μm-800μm is used
The tablets disintegrate within 5-10 seconds using the described European Pharmacopia Method
Example 1
Substance Amount [mg/Tabl.] Mass [%]
Active *) 50,25 30,15%
Prosoiv (SMMC 90)" ~io Cob 60,6 i%
L-HPC Type Bl 13,30 7,98%
Natrium 0,42 0,25%
Dodecylsulfat
NaCl 0,50 0,30%
Saccharin-Natrium 0,17 0,10%
Na-Stearyl-Fumarat ϊ.oδ 0,60%
Tablet 166,64" 100,00%
") used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol
Example 2
Substance , Amount [mg/Tabl.] Mass [%]
■ Active"*) "" " " " ■ 50,25 " 30~15%
Prosolv (SMMC 90) " 75,00 45,01 %
Avicel PH200 26,08 15,65%
L-HPC Type Bl " " """" 13,30 7,98%
Natrium " 0,42 O',25%"
Dodecylsulfat Na^,-, ;~ό,50 0,30%
Saccharin-Natrium '. 0,09 " " ' 0,05%
Na-Stearyl-Fumarat ' 1 ,00 ] 0,60%
Tablet " : 166,64 " 100,00%
*) used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol Example 3
Substance ; Amount [mg/Tabl.] Mass [%]
Active *) ; 50,25 30,21 % "
Prosolv (SMMC 90) ■ 45,00 27,"θ5% " "
Avicel PH200 ' ^ 26,08 15,68%
Arbocel P290 ! 25,00 15,03% "
L-HPC Type Bl : i 8,oo 15,82% "
Natrium : 0,42 0,25%"
Dodecylsulfat
NaCl" ■ 0,50 0,30%
Saccharin-Natrium ! 0,09 0,05%
Na-Stearyl-Fumarat ' 1 ,00 0,60%
Tablet ; 166,34 100,00%
*) used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol
Example 4
Substance '' Amount [mg/Tabl.] Mass [%]
Active *) ' 50,25 30,21 %
Prosolv (SMMC 90) 45,00 27,05% "
Arbocel 290 , 20,00 12,02%
Kollidon CL 749,08 29,51 %
Natrium ; 0,42 0,25%
Dodecylsulfat •
NaCl " 0,50 " 0,30%
Saccharin-Natrium ' 0,09 0,05%
Na-Stearyl-Fumarat . 1 ,00 "θ,6O% "
Tablet ■ 166,34 100,00% "
*) used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol Example 5
Substance Amount [mg/Tabl.] Mass [%]
Active *) 50,25 30,21 %
"Prosόϊv (SMMC 90)~ "45,00 27,05%
Arbocel 290 "ib.oό" "Ϊ8",04%
Kollid'on CL ' " 39,08 " 23,49%
Natrium 0,42 0,25%
Dodecylsulfat
NaCl" 0,50 ' " 0,30% "
Saccharin-Natrium 0,09 0,05%
Na-Stearyl-Fumarat 1 ,00 0,60%
Tablet 166,34 100,00%
*) used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol
Example 6
Substance Amount [mg/Tabl.] Mass [%]
Active *) ! 50,25 ' 30,21 %
Prosolv (SMMC 90) ' 45,00 ' 27,05%
Aqualon EC TIO ' 3~8,6θ " " 22,84%
Kolϊidon CL . 15,08 9,07%
L-HPC Type Bl ' 16,00 ' 9,62%
Natrium "θ,42 " " " 6,25%"
Dodecylsulfat
NaCl 1 0,50 ' 0,30% "
Saccharin-Natrium 1 0,09 ' 0,05%"
Na-Stearyl-Fumarat ] 1 ,00 ' 0,60%
Tablet i 166J4 "' 100,00%"
") used as 99.5% (m/m) Acarbose and 0.5% (m/m) Sodium stearyl fumerat or Miglitol

Claims

Claims:
1. A non-effervescent tablet for oral administration, comprising an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.
2. The tablet according to claim I 1 wherein said tablet exhibits oral disintegratability in not more than 60 seconds.
3. The tablet according to any of claims 1 to 2, wherein said water insoluble carrier is selected from the group Cellulose, microcrystalline Cellulose or silicified microcrystalline Cellulose or mixtures thereof.
4. The tablet according to claim 6, wherein said silicified microcrystalline cellulose is contained in an amount within the range of 20% to 90%.
5. The tablet according to claims 6-9, wherein said silicified microcrystalline cellulose has an average particle size within the range of 20-300 μm.
6. The tablet according to claim 1 - 5, wherein said desintegrant is selected from the group consisting of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, crosscarmelose sodium, crosspovidone (crosslinked Polyvinylpyrolidone), sodium starch glycolate, starch, and combinations thereof.
7. The tablet according to claim 1 - 6, wherein said surfactant is selected from the group Sodium dodecylsulfate, Polyoxyethylen Sorbitan fatty acid esters (Tweens), Polyoxyethylene Stearates, Sorbitan fatty acid esters (Spans) .
8. The tablet according to claims 1 -7, wherein said active agent is selected from the group consisting of pharmaceutical active agents, nutrients, nutriceuticals, and cosmetics.
9. The tablet according to claims 1 -8, wherein said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulcerics, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistaminics.
10. The tablet according to claims 1 -8, wherein said pharmaceutically active agent is selected from the group consisting of ibuprofen, acetominophen, piroxicam, leflunomide, ondansetron, granisetron, paracetamol, carbamazepin, lamotrigine, clozapine, olanzapine, risperidone, citalopram, paroxetine, sertraline, fluoxetine, fluvoxamine, zopiclon, Zolpidem, cimetidine, ranitidine, omeprazole, metoclopramide, cisapride, domperidon, zafirlukast, montelukast, prarnipexol, selegiline, Zolpidem, zopiclon, doxazosin, terazosin, atenolol, bisoprolol, amlodipine, nifedipine, diltiazem, enalapril, captopril, ramipril, losartan, glyceroltrinitrate, alfuzosin, finasteride, pravastatin, atorvastatin, simvastatin, gemfibrozil, metformin, terfenadine, loratadine, celecoxib, rifecoxib, and rivastigmine, as well as a pharmaceutically acceptable salt, ester, hydrate or solvate of the active agent.
1 1. Use of a surfactant for making an orally disintegratable non-effervescent pharmaceutical tablet.
EP08856436A 2007-12-08 2008-11-25 Oral dispersable tablet Withdrawn EP2231126A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08856436A EP2231126A2 (en) 2007-12-08 2008-11-25 Oral dispersable tablet

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023802 2007-12-08
PCT/EP2008/009968 WO2009071219A2 (en) 2007-12-08 2008-11-25 Oral dispersable tablet
EP08856436A EP2231126A2 (en) 2007-12-08 2008-11-25 Oral dispersable tablet

Publications (1)

Publication Number Publication Date
EP2231126A2 true EP2231126A2 (en) 2010-09-29

Family

ID=40631079

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08856436A Withdrawn EP2231126A2 (en) 2007-12-08 2008-11-25 Oral dispersable tablet

Country Status (9)

Country Link
EP (1) EP2231126A2 (en)
JP (2) JP2011506279A (en)
KR (1) KR20100096140A (en)
CN (1) CN101888834A (en)
BR (1) BRPI0820861A2 (en)
MX (1) MX2010005175A (en)
RU (1) RU2010128019A (en)
TW (1) TW200938233A (en)
WO (1) WO2009071219A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101560438B1 (en) * 2009-09-08 2015-10-14 교와 가가꾸고교 가부시키가이샤 Antacid and laxative tablet
CN101797236B (en) * 2010-03-23 2012-05-23 西南大学 Rivastigmine orally disintegration tablet and preparation method thereof
BR112012027303A2 (en) * 2010-04-27 2017-10-24 Bayer Ip Gmbh oral crumbling tablet containing acarbose
US20110300216A1 (en) * 2010-06-03 2011-12-08 First Eric R Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
JP5750856B2 (en) * 2010-10-04 2015-07-22 ライオン株式会社 Solid pharmaceutical composition and pharmaceutical preparation
KR101237646B1 (en) * 2010-12-09 2013-03-04 주식회사 드림파마 Solid dispersion comprising celecoxib with improved bioavailibity, pharmaceutical composition comprising the solid dispersion, and preparation method of the solid dispersion
FR2968992B1 (en) * 2010-12-16 2013-02-08 Sanofi Aventis ORODISPERSIBLE PHARMACEUTICAL TABLET BASED ON ZOLPIDEM
FR2968995B1 (en) * 2010-12-16 2013-03-22 Sanofi Aventis PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION TO PREVENT MEASUREMENT
TR201100150A2 (en) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Water soluble dosage forms
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
CN102600149B (en) * 2012-02-02 2013-12-04 西藏易明西雅生物医药科技有限公司 Pharmaceutical composition for treating diabetes
WO2015008825A1 (en) 2013-07-19 2015-01-22 株式会社三和化学研究所 Orally disintegrating tablet
JP6506752B2 (en) * 2013-07-19 2019-04-24 バイエル ファーマ アクチエンゲゼルシャフト Super fast disintegrating tablet formulation for API miglitol
CN103877041B (en) * 2014-03-14 2016-07-06 崔书豪 A kind of piroxicam dispersible tablet and preparation method thereof
WO2017130709A1 (en) 2016-01-29 2017-08-03 小林　光 Solid preparation, method for producing solid preparation, and method for generating hydrogen
CN105640954B (en) * 2016-02-04 2019-03-05 青岛市海慈医疗集团 It is a kind of to treat dyspeptic Cisapride tablet
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3482747A4 (en) * 2016-07-11 2020-03-04 Wuhan LL Science And Technology Development Co., Ltd. COMPOUND DISINTEGRANT SYSTEM AS DRY ORAL ADMINISTRATION FORMULATION AND DRY ORAL ADMINISTRATION FORMULATION CONTAINING THE SAME
JP6916184B2 (en) 2016-08-23 2021-08-11 株式会社Ｋｉｔ Formulation manufacturing method
CN110191699A (en) 2016-08-23 2019-08-30 小林光 Hydrogen supply material, method for producing the same, and method for supplying hydrogen
CN107334742B (en) * 2017-08-18 2020-01-31 山东力诺制药有限公司 fluoxetine hydrochloride dispersible tablet and preparation method thereof
KR20190037182A (en) * 2017-09-28 2019-04-05 한미약품 주식회사 Pharmaceutical composition comprising multi-unit spheroidal tablet containing esomeprazole and pharmaceutically acceptable salt thereof, and preparation method thereof
CN110840850B (en) * 2018-07-24 2023-03-17 烟台药物研究所 Celecoxib freeze-dried orally disintegrating tablet with high bioavailability and preparation method thereof
CN109864971B (en) * 2019-04-08 2021-12-17 西安远大德天药业股份有限公司 Granules of lamotrigine solid dispersion and preparation method thereof
CN114224855B (en) * 2021-12-01 2023-11-28 北京悦康科创医药科技股份有限公司 Doxazosin mesylate buccal tablet and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802700A1 (en) * 1998-01-24 1999-07-29 Bayer Ag Preparation of fast-dissolving tablets for controlling blood sugar levels
WO2003063831A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
JP4739217B2 (en) * 2003-05-07 2011-08-03 サムヤン コーポレイション Highly plastic granules for making fast dissolving tablets
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20070196477A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area calcium phosphates
US20070196474A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009071219A3 *

Also Published As

Publication number Publication date
KR20100096140A (en) 2010-09-01
JP2011506279A (en) 2011-03-03
JP2015038123A (en) 2015-02-26
RU2010128019A (en) 2012-01-20
WO2009071219A3 (en) 2009-09-11
MX2010005175A (en) 2010-08-02
TW200938233A (en) 2009-09-16
WO2009071219A2 (en) 2009-06-11
CN101888834A (en) 2010-11-17
BRPI0820861A2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
EP2231126A2 (en) Oral dispersable tablet
US20040265375A1 (en) Orally disintegrating tablets
JP6545839B2 (en) Orally disintegrating tablet and method for producing the same
US20110142931A1 (en) Soft tablet containing dextrose monohydrate
DK2510950T3 (en) DRY-COATED ORALT-DISINTEGRATING TABLE
JP2001058944A (en) Rapidly disintegrating solid formulation
JP5594285B2 (en) Orally disintegrating tablets
US7201922B2 (en) Orodispersible solid pharmaceutical form
Jadon et al. Taste masking of Lornoxicam by polymer carrier system and formulation of oral disintegrating tablets
JP5824524B2 (en) Orally disintegrating tablets containing hydroxyalkyl cellulose microparticles
JP2003034655A (en) Fast disintegrating solid preparation
JP2003176242A (en) Quickly disintegrable compression-molded material and method for producing the same
JP4601271B2 (en) COMPRESSION MOLDING AND METHOD FOR PRODUCING THE SAME
KR20180041217A (en) Ultra-high-speed disintegration tablet and its preparation method
JP4965096B2 (en) Compression molding
JP6443891B2 (en) Sustained release formulation
EP2905019A1 (en) Orally disintegrating tablet formulations of memantine
Nurdin et al. Development of Rapid Dispersible Tablet Preparations Using Synthetic and Natural Superdisintegrant Disintegrants: Comparative Performance Analysis
HK1146387A (en) Oral dispersable tablet
JP2010159289A (en) Compression molding preparation and method for producing the same
WO2020249500A1 (en) Stable tablet formulation of nifurtimox and process for producing the same
US20030228370A1 (en) Orodispersible solid pharmaceutical form

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100708

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20101029

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160601